Portzamparc Sponsored - MAAT PHARMA SA (MAAT) FLASH - MaaT Pharma - Acheter - Obj. 19.60€

Report

Portzamparc Sponsored

Clément Bassat

FLASH - MaaT Pharma - Acheter - Obj. 19.60€

Alors que les recrutements se poursuivent en Europe, la FDA demande de nouvelles informations sur MaaT013 dans son évaluation dans la maladie aiguë du greffon contre l'hôte.

11/08/2022 1 FR

Underlying

MAAT PHARMA SA

See profile

FR0012634822 Euronext Paris France

Provider

Portzamparc Sponsored

Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.

See profile

Analysts

Clément Bassat

Other Reports on these Companies

KBC Securities

MaaT Pharma FIRST LOOK: Additional EAP data supportive of MaaT013 in aGvHD

MaaT reported additional early access program (EAP) data for MaaT013 in 140 patients with aGvHD to be presented at EBMT, being held 14-17 April. The results continue to show solid ORR outcomes, and we are particularly encouraged by the 42% overall survival observed in the steroid and ruxolitinib refractory subset at 18 months, as this is a similar patient population to that of the phase 3 (ARES) trial - topline (GI-ORR) data from MaaT013's phase 3 is expected in mid 4Q24. We reiterate our BUY rating and € 15 TP.

April 15, 2024 April 15, 2024 1 EN

KBC Securities

Morning Notes : AGS BB, PROX BB, UCB BB, SHUR BB, MAAT FP, NXFIL NA

: AGS BB, PROX BB, UCB BB, SHUR BB, MAAT FP, NXFIL NA

April 15, 2024 April 15, 2024 1 EN

BusinessWire

MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event

LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer, presents a summary of its oral presentation at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) currently being hosted in Glasgow, Scotland from 14-17 April 2024. The presentation is scheduled for April 17th by Dr. Malard, Professor of Hematology at Saint-Antoine Hospital and Sorbonne University in P...

April 15, 2024 April 15, 2024 1 EN

La Matinale - 12-07-2023 - Portzamparc

EKINOPS : Un S1 de bonne facture / Contact – Acheter (1), obj. 10.6€ Cours: 7.78€ au 11/07/23 GTT : Commande de deux méthaniers – Acheter (1), obj. 122.0€ Cours: 96.8€ au 11/07/23 KALRAY : Objectif 2023 confirmé dans l’attente d’un gros S2 / Confcall – Acheter (1), obj. 38.5€ Cours: 28.9€ au 11/07/23 PLASTIVALOIRE : Progression de l’EBITDA et renforcement du bilan – Conserver (3), obj. 3.40€ Cours: 3.24€ au 11/07/23 SPINEWAY : Les récentes acquisitions sont à la hauteur – Acheter (1), obj. 2.20€ Cours: 0.41€ au 11/07/23 VOLTALIA : Nouveau Corporate PPA avec la SNCF / Contact – Acheter (1)...

July 12, 2023 July 12, 2023 1 FR

Nicolas Royot

Nicolas Royot

FLASH - Waga Energy - Strong Buy - TP: €30.0

As expected, Waga signed an important contract in the United States, which give credibility to the 2026 guidance and confirms the potential of the US market.

July 11, 2023 July 11, 2023 1 EN

Nicolas Royot

Nicolas Royot

FLASH - Waga Energy - Acheter - Obj. 30€

Comme espéré, Waga signe un contrat important aux Etats-Unis, qui crédibilise encore la guidance 2026 et confirme le potentiel du marché américain.

July 11, 2023 July 11, 2023 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

FLASH - MaaT Pharma - Acheter - Obj. 19.60€

MaaT Pharma FIRST LOOK: Additional EAP data supportive of MaaT013 in aGvHD

Morning Notes : AGS BB, PROX BB, UCB BB, SHUR BB, MAAT FP, NXFIL NA

MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event

La Matinale - 12-07-2023 - Portzamparc

FLASH - Waga Energy - Strong Buy - TP: €30.0

FLASH - Waga Energy - Acheter - Obj. 30€

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe